The Claim
In diet-induced obese C57BL/6N mice, a two-week combination of semaglutide and PG-110, a bispecific antibody targeting ActRII and myostatin, is associated with significantly greater fat mass reduction compared to semaglutide alone, while preserving lean mass and increasing hind limb bone mineral density.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In obese mice, a two-week treatment combining semaglutide and a bispecific antibody targeting ActRII and myostatin results in greater fat loss than semaglutide alone, without loss of muscle mass and with increased bone mineral density in the hind limbs.
See the scientific wording
In diet-induced obese C57BL/6N mice, a two-week combination of semaglutide and PG-110, a bispecific antibody targeting ActRII and myostatin, is associated with significantly greater fat mass reduction compared to semaglutide alone, while preserving lean mass and increasing hind limb bone mineral density.
A drug that blocks two signals that normally limit muscle growth and bone building works with another drug that reduces appetite and fat storage. Together, they cause the body to break down more fat, keep all its muscle, and build stronger bones by turning up the signals that make muscle and bone cells grow and turn down the signals that make fat cells store energy.
What the research says
1 studyIn obese mice, adding a special muscle-and-bone-boosting antibody to a weight-loss drug made them lose more fat and stronger bones, without losing muscle — exactly what the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.